Clinical characteristics and prognostic analysis of <scp>SMARCA4</scp>‐deficient non‐small cell lung cancer

Abstract

SMARCA4-dNSCLC has unique clinicopathological features and a shorter survival prognosis than SMARCA4-iNSCLC. The efficacy of immunotherapy combined with chemotherapy needs to be observed for longer periods.